Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
16,5 HKD | +0,98% | +11,34% | +18,71% |
26/04 | Kankermedicijn van Shanghai Henlius Biotech krijgt goedkeuring van Amerikaanse FDA | MT |
24/04 | Shanghai Henlius Biotech doseert 1e patiënt in klinische studie naar fibrosemedicijn in China | MT |
Vakgebied
Aantal werknemers: 3 637
Verkoop per activiteit
HKD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Biopharmaceutical
100,0
%
| 3 738 | 100,0 % | 5 961 | 100,0 % | +59,47% |
Verkoop per regio
HKD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
China
89,2
%
| 3 303 | 88,4 % | 5 316 | 89,2 % | +60,92% |
North America
5,8
%
| 169 | 4,5 % | 348 | 5,8 % | +106,21% |
Asia Pacific (excluding China)
3,6
%
| 208 | 5,6 % | 214 | 3,6 % | +3,00% |
Europe
1,0
%
| 58 | 1,6 % | 62 | 1,0 % | +6,83% |
South America
0,4
%
| - | - | 21 | 0,4 % | - |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Wei Dong Jiang
FOU | Founder | - | 01-12-09 |
Jun Zhu
CEO | Chief Executive Officer | 46 | 30-11-21 |
Wei Huang
PSD | President | 56 | 01-10-20 |
Wen Jie Zhang
CHM | Chairman | 57 | 01-03-19 |
Simon Hsu
CTO | Chief Tech/Sci/R&D Officer | - | - |
Miao Jie Chen
CMP | Compliance Officer | 41 | - |
Ye Xing Yuan
BRD | Director/Board Member | 39 | 01-01-23 |
Jin Li
LAW | General Counsel | - | 13-09-21 |
Jing Li
PRN | Corporate Officer/Principal | - | - |
Ping Cao
PRN | Corporate Officer/Principal | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Qi Yu Chen
BRD | Director/Board Member | 52 | 15-01-13 |
Xiao Hui Guan
BRD | Director/Board Member | 53 | 24-12-18 |
Yi Fang Wu
BRD | Director/Board Member | 54 | 12-06-15 |
Rui Lin Song
BRD | Director/Board Member | 61 | 02-09-19 |
De Yong Wen
BRD | Director/Board Member | 52 | 28-07-22 |
Guo Ping Zhao
BRD | Director/Board Member | 75 | 02-09-19 |
Wen Jie Zhang
CHM | Chairman | 57 | 01-03-19 |
Rong Li Feng
CHM | Chairman | 49 | 21-04-20 |
Jun Zhu
CEO | Chief Executive Officer | 46 | 30-11-21 |
Ye Xing Yuan
BRD | Director/Board Member | 39 | 01-01-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 380 066 312 | 0 | 0 | 15,03 % |
Aandeel B | 1 | 163 428 541 | 81 687 447 ( 49,98 %) | 0 |
Bedrijfsgegevens
Shanghai Henlius Biotech, Inc.
Innov Tower 1801 Hongmei Road, Xuhui District
200233, Shanghai
+
http://www.henlius.comSector
Verkoop per regio
Herzieningen van WPA
Winst van het jaar - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
+18,71% | 1,15 mld. | |
-4,66% | 86,13 mld. | |
+1,32% | 39,82 mld. | |
-19,27% | 30,42 mld. | |
+57,86% | 25,23 mld. | |
-16,09% | 15,36 mld. | |
-9,14% | 11,95 mld. | |
-17,69% | 11,6 mld. | |
-43,00% | 11,51 mld. | |
+5,24% | 8,71 mld. |
- Beurs
- Aandelen
- Koers 2696
- Onderneming Shanghai Henlius Biotech, Inc.